Physician profile
Robert Kennedy
NPI 1487278909
$1,846.29
in general payments reported to CMS, 2019-2025
21 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.24 · 2023: $288 · 2024: $30.98 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Travel and Lodging: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.23 |
| Travel and Lodging | $701.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,185.64 | 2023-2025 | Minimed 780g, Inceptiv |
| Novo Nordisk INC | $154.65 | 2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $45.77 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $42.07 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $40.87 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.38 | 2025 | Jardiance |
| Dexcom, INC. | $36.34 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $31.18 | 2025 | |
| Nevro Corp. | $30.98 | 2024 | Senza |
| Averitas Pharma INC. | $29.48 | 2025 | Qutenza |
| Chiesi USA, INC. | $27.71 | 2025 | Mycapssa |
| Theratechnologies INC. | $25.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.39 | 2025 | Recorlev |
| Madrigal Pharmaceuticals | $21.84 | 2025 | Rezdiffra |
| Aurinia Pharma U.S., INC. | $17.37 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $16.96 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $16.93 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $16.84 | 2025 | Repatha |
| Janssen Biotech, INC. | $16.49 | 2022 | |
| Mannkind Corporation | $14.68 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $14.34 | 2025 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.